Alios banks $60 million in HCV nucleotide analogue deal with Vertex
This article was originally published in Scrip
Hot off its US approval of its hepatitis C virus (HCV) protease inhibitor Incivek (telaprevir), which is expected to change the way the disease is treated, Vertex Pharmaceuticals has signed an exclusive worldwide licensing deal gaining the rights to two HCV nucleotide analogues from Alios BioPharma in exchange for $60 million up front.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.